I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office via EFS-Web on September 25, 2007 by Roxanne Holmes.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wahl *et al*. Confirmation No.: 1873 ApplicationNo.: 10/632,151 Art Unit:

Filed: July 30, 2003

ANTI-CD20 ANTIBODY-DRUG

CONJUGATES FOR THE

TREATMENT OF CANCER AND

IMMUNE DISORDERS

1644

Examiner: Ron Schwadron Attorney Docket No: 0020-00211US

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

AND

STATEMENTS UNDER 37 C.F.R. § 1.821(f); § 1.821(g); and § 1.825(b)

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

For:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") mailed August 28, 2007 in connection with the above-identified application.

Submitted concurrently herewith is a substitute computer readable form (CRF) copy of the Sequence Listing in the form of a text file (.txt) in compliance with 37 CFR § 1.821(e) and a substitute paper copy of the Sequence Listing in accordance with 37 CFR § 1.821(c).

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.